Potent Anti-amoebic Effects of Ibogaine, Voacangine and the Root Bark Alkaloid Fraction of Tabernaemontana arborea

Abstract

Plants of Tabernaemontana species have several pharmacological activities including antimicrobial effects. Amoebiasis continues to be a public health problem, with increasing evidence of resistance to metronidazole. In this study, we assessed the effect of the alkaloid fraction of T. arborea root bark and the alkaloids ibogaine and voacangine on the viability and infectivity of Entamoeba histolytica trophozoites. Cultures were exposed to 0.1 – 10 µg/mL for 24, 48 and 72 h, and viability was then determined using a tetrazolium dye reduction assay and type of cellular death analyzed by flow cytometry. Results showed that the alkaloid fraction, but mainly ibogaine and voacangine alkaloids, exhibited potent dose-dependent anti-amoebic activity at 24 h post-exposure (IC₅₀ 4.5 and 8.1 µM, respectively), comparable to metronidazole (IC₅₀ 6.8 µM). However, the effect decreased after 48 and 72 h of exposure to concentrations below 10 µg/mL, suggesting that the alkaloids probably were catabolized to less active derivatives by the trophozoites. The treatment of trophozoites with the IC_50 s for 24 h induced significant morphological changes in the trophozoites, slight increase in granularity, and death by apoptonecrosis. The capacity of T. arborea alkaloids to inhibit the development of amoebic liver abscesses in hamsters was evaluated. Results showed that even when the treatments reduced the number of amoebic trophozoites in tissue sections of livers, they were unable to limit the formation of abscesses, suggesting their rapid processing to inactive metabolites. This work leaves open the possibility of using Tabernaemontana alkaloids as a new alternative for amoebiasis control.

Key words

Entamoeba histolytica - Tabernaemontana arborea - Apocynaceae - ibogaine - voacangine - alkaloids - anti-amoebic - amoebic liver abscess

Publication History

Received: 21 December 2021

Accepted after revision: 25 March 2022

Accepted Manuscript online:
25 March 2022

Article published online:
22 July 2022

• References

• 1 Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, OʼDonnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope 3rd CA, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128 DOI: 10.1016/S0140-6736(12)61728-0.
• 2 Hegazi MA, Patel TA, El-Deek BS. Prevalence and characters of Entamoeba histolytica infection in Saudi infants and children admitted with diarrhea at 2 main hospitals at south Jeddah: A re-emerging serious infection with unusual presentation. Braz J Infect Dis 2013; 17: 32-40
• 3 Carrero JC, Reyes-López M, Serrano-Luna J, Shibayama M, Unzueta J, León-Sicairos N, de la Garza M. Intestinal amoebiasis: 160 years of its first detection and still remains as a health problem in developing countries. Int J Med Microbiol 2020; 310: 151358 DOI: 10.1016/j.ijmm.2019.151358.
• 4 Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basáñez MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, Bernabé E, Bhalla K, Bhandari B, Bikbov B, Bin Abdulhak A, Birbeck G, Black JA, Blencowe H, Blore JD, Blyth F, Bolliger I, Bonaventure A, Boufous S, Bourne R, Boussinesq M, Braithwaite T, Brayne C, Bridgett L, Brooker S, Brooks P, Brugha TS, Bryan-Hancock C, Bucello C, Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, Burstein R, Calabria B, Campbell B, Canter CE, Carabin H, Carapetis J, Carmona L, Cella C, Charlson F, Chen H, Cheng AT, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahiya M, Dahodwala N, Damsere-Derry J, Danaei G, Davis A, De Leo D, Degenhardt L, Dellavalle R, Delossantos A, Denenberg J, Derrett S, Des Jarlais DC, Dharmaratne SD, Dherani M, Diaz-Torne C, Dolk H, Dorsey ER, Driscoll T, Duber H, Ebel B, Edmond K, Elbaz A, Ali SE, Erskine H, Erwin PJ, Espindola P, Ewoigbokhan SE, Farzadfar F, Feigin V, Felson DT, Ferrari A, Ferri CP, Fèvre EM, Finucane MM, Flaxman S, Flood L, Foreman K, Forouzanfar MH, Fowkes FG, Fransen M, Freeman MK, Gabbe BJ, Gabriel SE, Gakidou E, Ganatra HA, Garcia B, Gaspari F, Gillum RF, Gmel G, Gonzalez-Medina D, Gosselin R, Grainger R, Grant B, Groeger J, Guillemin F, Gunnell D, Gupta R, Haagsma J, Hagan H, Halasa YA, Hall W, Haring D, Haro JM, Harrison JE, Havmoeller R, Hay RJ, Higashi H, Hill C, Hoen B, Hoffman H, Hotez PJ, Hoy D, Huang JJ, Ibeanusi SE, Jacobsen KH, James SL, Jarvis D, Jasrasaria R, Jayaraman S, Johns N, Jonas JB, Karthikeyan G, Kassebaum N, Kawakami N, Keren A, Khoo JP, King CH, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Laden F, Lalloo R, Laslett LL, Lathlean T, Leasher JL, Lee YY, Leigh J, Levinson D, Lim SS, Limb E, Lin JK, Lipnick M, Lipshultz SE, Liu W, Loane M, Ohno SL, Lyons R, Mabweijano J, MacIntyre MF, Malekzadeh R, Mallinger L, Manivannan S, Marcenes W, March L, Margolis DJ, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGill N, McGrath J, Medina-Mora ME, Meltzer M, Mensah GA, Merriman TR, Meyer AC, Miglioli V, Miller M, Miller TR, Mitchell PB, Mock C, Mocumbi AO, Moffitt TE, Mokdad AA, Monasta L, Montico M, Moradi-Lakeh M, Moran A, Morawska L, Mori R, Murdoch ME, Mwaniki MK, Naidoo K, Nair MN, Naldi L, Narayan KM, Nelson PK, Nelson RG, Nevitt MC, Newton CR, Nolte S, Norman P, Norman R, OʼDonnell M, OʼHanlon S, Olives C, Omer SB, Ortblad K, Osborne R, Ozgediz D, Page A, Pahari B, Pandian JD, Rivero AP, Patten SB, Pearce N, Padilla RP, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Phillips MR, Pierce K, Pion S, Polanczyk GV, Polinder S, Pope 3rd CA, Popova S, Porrini E, Pourmalek F, Prince M, Pullan RL, Ramaiah KD, Ranganathan D, Razavi H, Regan M, Rehm JT, Rein DB, Remuzzi G, Richardson K, Rivara FP, Roberts T, Robinson C, De Leòn FR, Ronfani L, Room R, Rosenfeld LC, Rushton L, Sacco RL, Saha S, Sampson U, Sanchez-Riera L, Sanman E, Schwebel DC, Scott JG, Segui-Gomez M, Shahraz S, Shepard DS, Shin H, Shivakoti R, Singh D, Singh GM, Singh JA, Singleton J, Sleet DA, Sliwa K, Smith E, Smith JL, Stapelberg NJ, Steer A, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Syed S, Tamburlini G, Tavakkoli M, Taylor HR, Taylor JA, Taylor WJ, Thomas B, Thomson WM, Thurston GD, Tleyjeh IM, Tonelli M, Towbin JA, Truelsen T, Tsilimbaris MK, Ubeda C, Undurraga EA, van der Werf MJ, van Os J, Vavilala MS, Venketasubramanian N, Wang M, Wang W, Watt K, Weatherall DJ, Weinstock MA, Weintraub R, Weisskopf MG, Weissman MM, White RA, Whiteford H, Wiebe N, Wiersma ST, Wilkinson JD, Williams HC, Williams SR, Witt E, Wolfe F, Woolf AD, Wulf S, Yeh PH, Zaidi AK, Zheng ZJ, Zonies D, Lopez AD, AlMazroa MA, Memish ZA. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197-2223 DOI: 10.1016/S0140-6736(12)61689-4.
• 5 Kapoor K, Chandra M, Nag D, Paliwal JK, Gupta RC, Saxena RC. Evaluation of metronidazole toxicity: a prospective study. Int J Clin Pharmacol Res 1999; 19: 83-88
• 6 Chacko M, Bhide SV. Carcinogenicity, perinatal carcinogenicity and teratogenicity of low dose metronidazole (MNZ) in Swiss mice. J Cancer Res Clin Oncol 1986; 112: 135-140 DOI: 10.1007/BF00404396.
• 7 Sisson G, Goodwin A, Raudonikiene A, Hughes NJ, Mukhopadhyay AK, Berg DE, Hoffman PS. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori . Antimicrob Agents Chemother 2002; 46: 2116-2123 DOI: 10.1128/AAC.46.7.2116-2123.2002.
• 8 Samarawickrema NA, Brown DM, Upcroft JA, Thammapalerd N, Upcroft P. Involvement of superoxide dismutase and pyruvate: ferredoxin oxidoreductase in mechanisms of metronidazole resistance in Entamoeba histolytica . J Antimicrob Chemother 1997; 40: 833-840
• 9 Wassmann C, Hellberg A, Tannich E, Bruchhaus I. Metronidazole resistance in the protozoan parasite Entamoeba histolytica is associated with increased expression of iron-containing superoxide dismutase and peroxiredoxin and decreased expression of ferredoxin 1 and flavin reductase. J Biol Chem 1999; 274: 26051-26056
• 10 Orozco E, Marchat LA, Gómez C, López-Camarillo C, Pérez DG. Drug resistance mechanisms in Entamoeba histolytica, Giardia lamblia, Trichomonas vaginalis, and opportunistic anaerobic Protozoa. In: Mayers D, Sobel J, Ouellette M, Kaye K, Marchaim D. eds. Antimicrobial Drug Resistance. Cham: Springer; 2009: 549-559
• 11 DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ 2003; 22: 151-185 DOI: 10.1016/S0167-6296(02)00126-1.
• 12 Kayser O, Kiderlen AF, Croft SL. Natural products as antiparasitic drugs. Parasitol Res 2003; 90: S55-S62 DOI: 10.1007/s00436-002-0768-3.
• 13 Silveira D, de Melo AF, Magalhães PO, Fonseca-Bazzo YM. Tabernaemontana Species: Promising Sources of New Useful Drugs. In: Atta-ur-Rahman. ed. Studies in Natural Products Chemistry. Volume 54. Amsterdam, The Netherlands: Elsevier; 2017: 227-289
• 14 Alvarado-Cárdenas LO, Lozada-Pérez L, Cadena RJ, Islas-Hernández S, Martínez-González CR, Cortez CEB, González-Martínez CA, González-Ramírez IS. The triad of knowledge: Systematic, diversity and conservation status of the Mexican species of Tabernaemontana (Apocynaceae; Rauvolfioideae: tribe Tabernaemontaneae). Phytotaxa 2019; 388: 1-46 DOI: 10.11646/phytotaxa.388.1.1.
• 15 Naidoo CM, Naidoo Y, Dewir YH, Murthy HN, El-Hendawy S, Al-Suhaibani N. Major Bioactive Alkaloids and Biological Activities of Tabernaemontana Species (Apocynaceae). Plants (Basel) 2021; 10: 313 DOI: 10.3390/plants10020313.
• 16 Pallant CA, Cromarty AD, Steenkamp V. Effect of an alkaloidal fraction of Tabernaemontana elegans (Stapf.) on selected micro-organisms. J Ethnopharmacol 2012; 140: 398-404 DOI: 10.1016/j.jep.2012.01.036.
• 17 Ruttoh EK, Tarus PK, Bii CC, Machocho AK, Karimie LK, Okemo PO. Antibacterial activity of Tabernaemontana stapfiana britten (Apocynaceae) extracts. Afr J Tradit Complement Altern Med 2009; 6: 186-194
• 18 Marathe NP, Rasane MH, Kumar H, Patwardhan AA, Shouche YS, Diwanay SS. In vitro antibacterial activity of Tabernaemontana alternifolia (Roxb) stem bark aqueous extracts against clinical isolates of methicillin resistant Staphylococcus aureus . Ann Clin Microbiol Antimicrob 2013; 12: 26 DOI: 10.1186/1476-0711-12-26.
• 19 Luo X, Pires D, Aínsa JA, Gracia B, Mulhovo S, Duarte A, Anes E, Ferreira MJ. Antimycobacterial evaluation and preliminary phytochemical investigation of selected medicinal plants traditionally used in Mozambique. J Ethnopharmacol 2011; 137: 114-120 DOI: 10.1016/j.jep.2011.04.062.
• 20 Mohamad S, Ismail NN, Parumasivam T, Ibrahim P, Osman H, Wahab HA. Antituberculosis activity, phytochemical identification of Costus speciosus (J. Koenig) Sm., Cymbopogon citratus (DC. Ex Nees) Stapf., and Tabernaemontana coronaria (L.) Willd. and their effects on the growth kinetics and cellular integrity of Mycobacterium tuberculosis H37Rv. BMC Complement Altern Med 2018; 18: 5 DOI: 10.1186/s12906-017-2077-5.
• 21 Guzmán-Gutiérrez SL, Silva-Miranda M, Krengel F, Huerta-Salazar E, León-Santiago M, Díaz-Cantón JK, Espitia Pinzón C, Reyes-Chilpa R. Antimycobacterial Activity of Alkaloids and Extracts from Tabernaemontana alba and T. arborea . Planta Med 2022; 88: 53-61 DOI: 10.1055/a-1157-1732.
• 22 Marie-Magdeleine C, Mahieu M, DʼAlexis S, Philibert L, Archimede H. In vitro effects of Tabernaemontana citrifolia extracts on Haemonchus contortus . Res Vet Sci 2010; 89: 88-92 DOI: 10.1016/j.rvsc.2010.01.002.
• 23 Bapela MJ, Meyer JJ, Kaiser M. In vitro antiplasmodial screening of ethnopharmacologically selected South African plant species used for the treatment of malaria. J Ethnopharmacol 2014; 156: 370-373 DOI: 10.1016/j.jep.2014.09.017.
• 24 Muthaura CN, Keriko JM, Mutai C, Yenesew A, Gathirwa JW, Irungu BN, Nyangacha R, Mungai GM, Derese S. Antiplasmodial potential of traditional antimalarial phytotherapy remedies used by the Kwale community of the Kenyan Coast. J Ethnopharmacol 2015; 170: 148-157 DOI: 10.1016/j.jep.2015.05.024.
• 25 Nor Azman NS, Hossan MS, Nissapatorn V, Uthaipibull C, Prommana P, Jin KT, Rahmatullah M, Mahboob T, Raju CS, Jindal HM, Hazra B, Mohd Abd Razak MR, Prajapati VK, Pandey RK, Aminudin N, Shaari K, Ismail NH, Butler MS, Zarubaev VV, Wiart C. Anti-infective activities of 11 plants species used in traditional medicine in Malaysia. Exp Parasitol 2018; 194: 67-78 DOI: 10.1016/j.exppara.2018.09.020.
• 26 Amelia P, Nugroho AE, Hirasawa Y, Kaneda T, Tougan T, Horii T, Morita H. Two new sarpagine-type indole alkaloids and antimalarial activity of 16-demethoxycarbonylvoacamine from Tabernaemontana macrocarpa Jack. J Nat Med 2019; 73: 820-825 DOI: 10.1007/s11418-019-01317-4.
• 27 Bradacs G, Maes L, Heilmann J. In vitro cytotoxic, antiprotozoal and antimicrobial activities of medicinal plants from Vanuatu. Phytother Res 2010; 24: 800-809 DOI: 10.1002/ptr.2981.
• 28 Carothers S, Nyamwihura R, Collins J, Zhang H, Park H, Setzer WN, Ogungbe IV. Bauerenol Acetate, the pentacyclic triterpenoid from Tabernaemontana longipes, is an antitrypanosomal agent. Molecules 2018; 23: 355 DOI: 10.3390/molecules23020355.
• 29 Krengel F, Herrera Santoyo J, Olivera Flores TJ, Chávez Ávila VM, Pérez Flores FJ, Reyes Chilpa R. Quantification of anti-addictive alkaloids ibogaine and voacangine in in vivo- and in vitro-grown plants of two Mexican Tabernaemontana species. Chem Biodivers 2016; 13: 1730-1737 DOI: 10.1002/cbdv.201600146.
• 30 Díaz-Godínez C, Ontiveros-Rodríguez JC, Ríos-Valencia DG, Herbert-Pucheta JE, Zepeda-Vallejo LG, Carrero JC. Anti-amoebic activity of leaf extracts and aporphine alkaloids obtained from Annona purpurea . Planta Med 2020; 86: 425-433 DOI: 10.1055/a-1111-9566.
• 31 Cervantes-Rebolledo C, Moreno-Mendoza N, Morales-Montor J, De la Torre P, Laclette JP, Carrero JC. Gonadectomy inhibits development of experimental amoebic liver abscess in hamsters through downregulation of the inflammatory immune response. Parasite Immunol 2009; 31: 447-456 DOI: 10.1111/j.1365-3024.2009.01120.x.
• 32 Gakuya DW, Itonga SM, Mbaria JM, Muthee JK, Musau JK. Ethnobotanical survey of biopesticides and other medicinal plants traditionally used in Meru central district of Kenya. J Ethnopharmacol 2013; 145: 547-553 DOI: 10.1016/j.jep.2012.11.028.
• 33 Jamil S, Ahmad S, Akhtar J, Alam K. Antiamoebic plants used in Unani system of medicine. Nat Prod Radiance 2003; 2: 1-6
• 34 van Beek TA, Deelder AM, Verpoorte R, Svendsen AB. Antimicrobial, antiamoebic and antiviral screening of some Tabernaemontana species. Planta Med 1984; 50: 180-185 DOI: 10.1055/s-2007-969666.
• 35 Debnath A, Parsonage D, Andrade RM, He C, Cobo ER, Hirata K, Chen S, García-Rivera G, Orozco E, Martínez MB, Gunatilleke SS, Barrios AM, Arkin MR, Poole LB, McKerrow JH, Reed SL. A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target. Nat Med 2012; 18: 956-960
• 36 Capparelli EV, Bricker-Ford R, Rogers MJ, McKerrow JH, Reed SL. Phase I clinical trial results of auranofin, a novel antiparasitic agent. Antimicrob Agents Chemother 2016; 61: e01947-e02016
• 37 Babiaka SB, Simoben CV, Abuga KO, Mbah JA, Karpoormath R, Ongarora D, Mugo H, Monya E, Cho-Ngwa F, Sippl W, Loveridge EJ, Ntie-Kang F. Alkaloids with anti-onchocercal activity from Voacanga africana stapf (Apocynaceae): Identification and molecular modeling. Molecules 2020; 26: 70 DOI: 10.3390/molecules26010070.
• 38 Soares DC, Pereira CG, Meireles MA, Saraiva EM. Leishmanicidal activity of a supercritical fluid fraction obtained from Tabernaemontana catharinensis . Parasitol Int 2007; 56: 135-139 DOI: 10.1016/j.parint.2007.01.004.
• 39 Keene AT, Harris A, Phillipson JD, Warhurst DC. In vitro amoebicidal testing of natural products; Part I. Methodology. Planta Med 1986; 52: 278-285
• 40 Griffin CE, Hoke JM, Samarakoon U, Duan J, Mu J, Ferdig MT, Warhurst DC, Cooper RA. Mutation in the Plasmodium falciparum CRT protein determines the stereospecific activity of antimalarial cinchona alkaloids. Antimicrob Agents Chemother 2012; 56: 5356-5364 DOI: 10.1128/AAC.05667-11.
• 41 Carrero JC, Petrossian P, Olivos A, Sánchez-Zerpa M, Ostoa-Soloma P, Laclette JP. Effect of cyclosporine A on Entamoeba histolytica . Arch Med Res 2000; 31: S8-S9 DOI: 10.1016/s0188-4409(00)00188-0.
• 42 Baumann MH, Rothman RB, Pablo JP, Mash DC. In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats. J Pharmacol Exp Ther 2001; 297: 531-539
• 43 Mair CE, de Miranda Silva C, Grienke U, Kratz JM, Carreño F, Zimmermann ES, de Araújo BV, Dalla Costa T, Rollinger JM. Pharmacokinetics of hERG channel blocking voacangine in Wistar rats applying a validated LC-ESI-MS/MS method. Planta Med 2016; 82: 1030-1038 DOI: 10.1055/s-0042-107800.
• 44 Olivos-García A, Nequiz-Avendaño M, Tello E, Martínez RD, González-Canto A, López-Vancell R, García de León MC, Montfort I, Pérez-Tamayo R. Inflammation, complement, ischemia and amoebic survival in acute experimental amoebic liver abscesses in hamsters. Exp Mol Pathol 2004; 77: 66-71 DOI: 10.1016/j.yexmp.2003.09.003.